Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

Launched by UNIVERSITY OF MINNESOTA · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of tranexamic acid (TXA), a medication that helps prevent excessive bleeding, during facelift surgery. The study aims to find out if applying TXA directly to one side of the face during the procedure can reduce bleeding compared to a saline solution (saltwater) on the other side. Participants will be randomly assigned to receive different formulations of TXA or saline, helping researchers understand the best way to use this medication safely and effectively.

To be eligible for this trial, participants must be at least 18 years old, able to speak English, and considered healthy enough for facelift surgery by their surgeon. People who have previously had a bad reaction to TXA or who choose not to participate will not be included. If you join the study, you can expect to have the TXA or saline applied during your facelift, and you will be monitored for any side effects. This research is important as it may help improve surgical outcomes for patients undergoing facelift procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible participants will consist of all regular clinic patients who elect and are deemed fit by the surgeon to undergo facelift surgery, including patients undergoing ancillary procedures
• • age 18 and older
• • English speaking.
• Exclusion Criteria:
• • younger than 18
• • previously had an adverse reaction to tranexamic acid
• • non-English speaking
• • patients who elect not to participate or withdraw from the study.